Clinical Therapeutics/New Technology-Oral Agents

Clinical Therapeutics/New Technology-Oral Agents

You have access
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
Ofri Mosenzon, Stephen D. Wiviott, Hiddo J.L. Heerspink, Jamie P. Dwyer, Avivit Cahn, Erica L. Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Martin Fredriksson, Peter A. Johansson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Marc S. Sabatine, Itamar Raz

Diabetes Care Jul 2021, dc210076; DOI: 10.2337/dc21-0076
You have access
Fenofibrate Use Is Associated With Lower Mortality and Fewer Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance Service Cohort
Sang-Ho Jo, Hyewon Nam, Jeongwoo Lee, Sojeong Park, Jungkuk Lee, Dae-Sung Kyoung

Diabetes Care Jun 2021, dc201533; DOI: 10.2337/dc20-1533
Open Access
Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
Ian J. Neeland, Takatoshi Kasai, Silvio E. Inzucchi, Brian S. Wojeck, Henry K. Yaggi, Odd Erik Johansen

Diabetes Care Jun 2021, 44 (6) e137-e138; DOI: 10.2337/dci21-0009
Open Access
Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
Shay Brikman, Guy Dori

Diabetes Care Jun 2021, 44 (6) e136; DOI: 10.2337/dc21-0310
Open Access
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
Roselle A. Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A. Fielding, Agampodi Mendis, Sigurd Johnsen, A. Margot Umpleby, Melanie Davies, David L. Russell-Jones

Diabetes Care Mar 2021, 44 (3) e61; DOI: 10.2337/dci20-0072
Open Access
Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
Geremia B. Bolli, Francesca Porcellati, Paola Lucidi, Carmine G. Fanelli

Diabetes Care Mar 2021, 44 (3) e59-e60; DOI: 10.2337/dc20-2575
Open Access
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
Guillaume Grenet, Samia Mekhaldi, Sabine Mainbourg, Marine Auffret, Catherine Cornu, Jean-Luc Cracowski, François Gueyffier, Jean-Christophe Lega, Michel Cucherat

Diabetes Care Mar 2021, 44 (3) e36-e37; DOI: 10.2337/dc20-2018
Open Access
Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
Andrea Giaccari, Anna Solini, Simona Frontoni, Stefano Del Prato

Diabetes Care Mar 2021, 44 (3) 647-654; DOI: 10.2337/dc20-1964
Open Access
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes
Klara R. Klein, Jennifer L.R. Freeman, Imogene Dunn, Chris Dvergsten, M. Sue Kirkman, John B. Buse, Carmen Valcarce

Diabetes Care Apr 2021, 44 (4) 960-968; DOI: 10.2337/dc20-2684
Open Access
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial
Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean-Marie Grouin, Kohjiro Ueki

Diabetes Care Apr 2021, 44 (4) 952-959; DOI: 10.2337/dc20-0763

Main menu

User menu

Search

Clinical Therapeutics/New Technology-Oral Agents

Pages

Navigate

More Information

Other ADA Resources